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Estrogen improves endothelial function 
Subodh Arora, MD, Aristidis Veves, MD, A. Enrique Caballaro, MD, Paula 
Smakowski, MS, PT, and Frank W. LoGerfo,  MD, Boston, Mass. 
Purpose: To determine the effect of estrogen on endothelium-dependent rdaxation in 
the cutaneous microcirculation ofwomen. 
Methods: Three groups of women participated in the study. Group 1 (n = 20) was pre- 
menopausal nd had a mean age of 39 years (range 24-50 years). Group 2 (n = 9) was 
postmenopausal and had a mean age of 58 years (range 53-65 years). Group 3 (n = 11) 
was postmenopausal and taking estrogen replacement therapy; the mean age was 53 
years (range 43-58 years). Eleven women in group 1 underwent testing twice, once dur- 
ing menstruation (mean serum estradiol level 73 _+ 30 pg/ml) and once during midcycle 
(mean serum estradiol level 268 -+ 193 pg/ml; p = 0.003). Single-point laser Doppler 
ultrasound and laser Doppler imaging with a Scanner were used to measure vasodilata- 
tion in the forearm skin in response to iontophoresis of 1% acetylcholine ( ndothelium 
dependent) and 1% sodium nitroprusside (endothelium-independent smooth muscle 
relaxant). 
Results: All three groups were matched for body mass index and fasting glucose, total, 
high-density lipoprotein, and low-density lipoprotein cholesterol and triglyceride l vels. 
All women had normal blood pressure, and none smoked. Mean serum estradiol levels 
were 196 ± 170 pg/ml (group 1), 35 ± 12 pg/ml (group 2), and 107 _* 78 pg/ml 
(group 3) (p = 0.004). Maximum microvascular vasodilatation (percentage increase over 
baseline) in response to acetylcholine was reduced in group 2 (93% ± 43%) compared 
with group 1 (187% _+ 63%) and group 3 (142% ± 56%) (p = 0.001). The response to 
sodium nitroprusside also was diminished in group 2 (73% ± 27%) compared with group 
1 (126% _+ 45%) and group 3 (100% _+ 32%) (p = 0.02). Within group 1 the acetylcholine 
response was higher during the midcycle phase (186% ± 31%) compared with the men- 
strual phase (147% ± 57%) (p < 0.05). The sodium nitroprusside r sponse also was high- 
er during the midcycle phase (144% ± 31%) compared with e menstrual phase (94% ± 
41%) (p < 0.05) 
Conclusion: The results indicate that estrogens might enhance ndothelium-dependent 
and endothelium-independent vasodilatation i  the microcirculation fwomen. (J Vasc 
Surg 1998;27:1141-7.) 
The lower incidence of cardiovascular events 
among premenopausal women and postmenopausal 
women taking estrogen replacement therapy has 
been ascribed to a cardioprotective effect of estro- 
gens. >4 Cardiovascular disease accounts for 23% of 
deaths among womcn in thc United Statcs, and the 
incidence is increasing, especially among post- 
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menopausal women.5 The mechanisms that underlie 
the cardioprotective effect of estrogen are the sub- 
jcct of  much interest. One of  the mechanisms 
appears to be a reduction in low-density lipoprotein 
cholesterol levels and an increase in high-density 
lipoprotein cholesterol levels, which may account for 
only 25% to 50% of the reduction in cardiovascular 
events. A direct effect of estrogen on the vessel wall 
may account for the remainder of  the beneficial 
effcct on cardiovascular function. 
Endothelial dysfunction has been suggested as 
one of the initial stages in the dcvelopment of ather- 
osclerosis and might be the result of reduced release 
of nitric oxide. 6 Studies have suggested that estro- 
gen might enhance the activity of endothelium- 
derived relaxing factor (nitric oxide) in the macro- 
circulation, thcrcby prcvcnting coronary vasocon- 
striction and thrombosis. In these studies duplcx 
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ultrasound was used to examine the effect of estro- 
gen on flow-mediated vasodilatation of the brachial 
artery.7, 8 Flow-mediated vasodilatation is known to 
be an endothelium-dependent phenomenon and can 
be measured uring reactive hyperemia by means of 
high-resolution ultrasound scanning of superficial 
arteries. 
The effect of estrogen on the cutaneous micro- 
circulation has not been evaluated selectively in the 
past. We hypothesized that endothelium-dependent 
vasodilatation i the cutaneous microcirculation is 
affected by serum estrogen (endogenous or exoge- 
nous) levels. To test this hypothesis we studied the 
effect of normal ovarian estrogen (endogenous) 
fluctuations during the menstrual cycle and the 
effect of estrogen replacement (exogenous) therapy 
on endothelial function in the cutaneous microcir- 
culation after menopause. 
METHODS 
Subjects. Three groups of female subjects were 
studied. Group 1 was premenopausal (n = 20, mean 
age 39 years, range 18 to 45 years). This group 
underwent testing at two points in the menstrual 
cycle, once during the menstrual period (low serum 
estrogen levels) and once midcycle (10 to 14 days 
after menses, high serum estrogen levels). Group 2 
was postmenopausal (n = 9, mean age 58 years, 
range 53 to 65 years). Group 3 was postmenopausal 
and taking estrogen replacement therapy (n = 11, 
mean age 53 years, range 43 to 58 years). Subjects 
were recruited randomly by means of intrahospital 
advertisement. For comparisons between the three 
groups midcycle estrogen levels and the midcycle 
vasodilatory response for group 1 were used for 
analysis. 
All subjects were healthy and had no symptoms. 
The premenopausal group had regular menstrual 
cycles (26 to 30 days) and the postmenopausal 
women had been postmenopausal for at least 2 
years. P0stmenopausal women taking estrogen 
replacement therapy hadbeen taking the medication 
for at least 1 year. The exclusion criteria included 
current smoking, diabetes, hypertension, anemia 
(hematocrit <35%), severe dyslipidemia, triglyceride 
levels >600 mg/dl, cholesterol level >250 mg/dl, 
and use of the following medications: lipid-lowering 
agents, glucocorticoids, bronchodilators, antineo- 
plastic agents, antibiotics, and oral contraceptives if 
premenopausal. The study was approved by the 
institutional review board. All subjects igned a writ- 
ten informed-consent form after listening to an 
explanation of the study design and methods. 
All tests were performed on the same day in a 
warm environment (room temperature 25 to 26 ° C) 
under fasting conditions. Cutaneous perfusion was 
measured on the flexor aspect of the left forearm for 
all subjects at the same distance from the elbow, 
midway between the elbow and the wrist joint. 
There was no history of peripheral vascular disease, 
and all subjects had a palpable radial pulse. Women 
in group 3 were taking the following hormone 
replacement therapy: estrogen only Estraderm patch 
(n = 4), estrogen only Premarin (n = 2), estrogen 
plus progesterone Premarin/Provera (n = 3), and 
estrogen only Estrase (n = 1). 
LASER DOPPLER IMAGING AND ION- 
TOPHORESIS. 
The term "iontophoresis denotes the introduction 
of soluble ions into the human skin by means of 
application of electric current. It is a noninvasive 
technique that avoids any systemic effects of the 
drugs used. Endothelium-dependent vasodilatation 
was measured with application of acetylcholine chlo- 
ride (acetylcholine induces release of nitric oxide 
from endothelium). Endothelium-independent 
vasodilatation was measured with sodium nitroprus- 
side (sodium nitroprusside causes direct relaxation 
of smooth muscle cells). The MIC1 iontophoresis 
system (Moor Instruments, Millwey, Devon, 
England) was used in this study. One percent acetyl- 
choline and 1% sodium nitroprusside in deionized 
water were delivered subdermally through an ion- 
tophoresis chamber with an anodal current of 200 
microamperes for 30 seconds. 
Laser Doppler perfusion imaging measurements 
before and after iontophoresis of acetylcholine and 
sodium nitroprusside were made for all participants. 
A laser Doppler perfusion imager (Lisca PIM 1.0; 
Lisca Development, Linkoping, Sweden) was used 
to map skin perfusion. A 1 mW helium-neon laser 
beam of 633 nm wavelength sequentially scans an 
area of the forearm. The maximum number of mea- 
sured points i  4096, and the apparatus produces a
color-coded image of skin erythrocyte flux on a 
computer monitor. Each measurement lasts 20 to 30 
seconds. The usual response to iontophoresis con- 
sists of transient erythema directly under the ion- 
tophoresis chamber. This technique has been shown 
by our group to have satisfactory reproducibility 
with a coefficient of variation less than 15%. 9 
Blood specimens. 
At the end of the noninvasive test a 10 to 15 ml 
blood specimen was drawn from the same arm as the 
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Table I. Demographic and serum profiles of study subjects 
Characteristic Group 1 Group 2 Group 3 p Value 
20 9 11 No. of  patients 
Age (yr;range) 39 (24-50) 58 (53-65) 53 (43-58) 
Body mass index 25 + 4.5 29 ± 6 26 • 6 
Systolic blood pressure (mm Hg) 119 • 10 121 • 6 121 • 11 
Diastolic blood pressure (mm Hg) 71 +_ 7 75 • 5 74 • 5 
Fasting glucose (mg/d l )  84 • 14 90 • 25 88 • 9 
Total cholesterol (mg/d l )  168 • 21 201 • 36 184 • 43 
High-density lipoprotein cholesterol (mg/dl )  45 • 9 44 • 11 54 • I2 
Low-density lipoprotein cholesterol (mg/dl )  108 • 17 136 • 26 118 • 25 
Triglycerides (mg/dl )  75 • 37 103 ± 22 112 • 63 
Estradiol (pg/ml)  186 • 31 35 • 12 107 • 78 
Group 1 vs  groups 
2 and 3, p < 0.05 
NS 
NS 
NS 
NS 
0.37 
0.38 
0.09 
0.83 
Groups 1 and 3 vs 
group 2, p < 0.05 
Values are mean value + SD. 
NS, No statistical difference. 
test from each subject. High-density lipoprotein, 
low-density lipoprotein, and total cholesterol, 
triglyceride, fasting glucose, and estradiol levels were 
measured. 
History and physical examination. 
All subjects had a medical history taken. Blood 
pressure, weight, height, and body mass index were 
obtained. 
Statistical analysis. 
The statistical power of the study was 0.80 at an 
level of 0.05 capable of showing a 20% difference 
in microvascular changes among the various groups. 
For statistical analysis the Minitab statistical package 
was used. Analysis of variance was used for compar- 
isons among the three groups, and Fisher test was 
used for pairwise differences between level means. 
All variables were treated as independent variables. 
The Kruskal Wallis test was used for nonparametri- 
cally distributed ata. The default error was 0.05. 
Results were expressed as mean _+ SD. 
RESULTS 
Demographic data, body mass index, lipid pro- 
files, and fasting glucose and estrogen levels are 
shown in Table I. All three groups were matched for 
body mass index, blood pressure, normal ipid pro- 
file, and fasting glucose level. There was no signifi- 
cant difference in lipid profiles of postmenopausal 
women using transdermal estrogen and those taking 
oral estrogen. Because it was not possible to match 
the age of the premenstrual group with that of the 
postmenstrual group, only group 2 and group 3 
were matched for age. Blood pressure measurements 
among group 1 were similar. Mean serum estradiol 
levels were significantly different for the three 
groups (p = 0.004). Eleven premenopausal women 
underwent testing during both the menstrual phase 
and the midcycle phase. Menstrual phase estrogen 
levels (73 _+ 30 pg/ml) were significantly lower than 
midcycle levels (268 + 193 pg/ml) (p < 0.05). 
The cutaneous temperature at which the ion- 
tophoresis and laser Doppler imaging were per- 
formed was not statistically different among the 
three groups (Table II). Mean baseline skin perfu- 
sion before iontophoresis was similar for group 1 
and group 3 (0.6 + 0.06 volts and 0.67 + 0.10 volts) 
but significantly lower for group 2 (0.55 + 0.04 
volts). 
Maximum microvascular vasodilatation (percent- 
age increase over baseline) in response to ion- 
tophoresis of acetylcholine was reduced in group 2 
(93% _+ 43%) compared with group 1 (187% _+ 63%) 
and group 3 (142% _+ 56%) (p = 0.001). The 
response to sodium nitroprusside also was dimin- 
ished in group 2 (73% _+ 27%) compared with group 
1 (126% _+ 45%) and group 3 (100% +_ 32%) (p = 
0.02) (Fig. 1). There was no significant difference in 
vasodilatory response to acetylcholine and sodium 
nitroprusside between women using transdermal 
estrogen and women taking oral estrogen. Within 
group 1, acetylcholine response was higher during 
the midcycle phase (I86% ± 31%) compared with the 
menstrual phase (147% _+ 57%) (p < 0.05). The sodi- 
um nitroprusside response was also higher during 
the midcycle phase (144% _+ 31%) compared with the 
menstrual phase (94% + 41%) (p < 0.05) (Fig. 2). 
DISCUSSION 
The cardioprotective effects of estrogen have 
been fairly well documented.l-4,10-13 The effect of 
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Table II. Cutaneous perfusion before and after iontophoresis of acetylcholine and sodium nitroprusside 
Characteristic Group 1 Group 2 Group 3 p Value 
Sldn temperature (oC) 
Perfusion before Ach (V) 
Perfusion before NaNP (V) 
Perfusion after 
Ach (V) 
Perfusion after NaNP (V) 
Percentage increase 
over baseline after Ach 
iontophoresis 
Percentage increase 
over baseline after NaNP 
iontophoresis 
31 + 0.8 30.7 + 0.8 30.7 +_ 0.7 NS 
0.63 +_ 0.06 0.56 ± 0.06 0.67 ± 0.10 Groups 1 and 3 vs 
group 2, 20 < 0.05 
0.65 -+ 0.07 0.55 -+ 0.04 0.70 -+ 0.11 Groups 1 and 3 vs 
group 2, p < 0.05 
1.89 _+ 0.49 1.17 _+ 0.25 1.66 e 0.44 Groups 1 and 3 vs 
group 2, p < 0.05 
1.49 -+ 0.30 1.05 ± 0.26 1.44 _+ 0.32 Groups 1 and 3 vs 
group 2, p < 0.05 
187 _+ 63 93 -+ 43 142 ± 56 Groups 1 and 3 vs 
group 2, p < 0.05 
126 _+ 45 73 _+ 27 100 + 32 Groups i and 3 vs 
group 2, p < 0.05 
Values are mean value + SD. 
NS, No statistical difference; Ach, acetylcholine; NaNP, sodium nitroprusside 
estrogen on the microcirculation of women has not 
been studied. We performed a quantitative study of 
the vasodilatory response of the cutaneous microcir- 
culation with a noninvasive method that has been 
validated.14,15 We found that both the endothelium- 
dependent and endothelium-independent vasodila- 
tory response in the microcirculation was signifi- 
cantly greater during the midcycle phase than the 
menstrual phase ofpremenopansal women. The two 
phases were confirmed with appropriate serum estra- 
diol levels, which were significantly higher during 
the midcycle phase than the menstrual phase (p < 
0.05). These findings suggested that endothelial 
vasodilatory function may be positively modulated 
with endogenous ovarian hormones, especially 
estrogen. 
Our results among postmenopausal women clear- 
ly demonstrated a significant difference in both 
endothelitun-dependent and -independent vasodila- 
tory response between women using estrogen 
replacement and those not using replacement. 
Women using hormone replacement had significant- 
ly higher serum levels of estradiol (p < 0.05) and had 
a much greater esponse to both acetylcholine (p < 
0.01) and sodium nitroprusside (p < 0.05). These 
findings suggest that estrogen positively affects both 
endothelium-dependent andendothelium-indepen- 
dent vasodilatation i the microcirculation. Because 
all our study subjects had no obvious associated car- 
diovascular risk factors, this improved vasodilatory 
response can be ascribed to the presence of estrogen. 
Localization of estrogen receptors on vascular 
endothelium and vascular smooth muscle cells of sev- 
eral mammalian species also suggests that these hor- 
moncs may influence vascular function directly.16,17 
Previous studies on the macrocirculafion have 
demonstrated that estrogen augments dothelium- 
dependent vasodilatation, as-20 Lieberman et al. 7 
showed that estrogen improves endothelium-depen- 
dent, flow-mediated vasodilatation in post- 
menopausal women. Those authors used duplex 
ultrasonography to measure changes in brachial 
artery diameter in response to reactive hyperemia. 
All their study subjects had mild hypercholes- 
terotemia, nd thus the results cannot necessarily be 
extrapolated topostmenopausal women with normal 
lipid profiles. It is also possible that the effect of 
estrogen on endothelium-dependent vasodilatation 
occurred as a result of the lipid-lowering effect of 
estrogen and not a direct effect of estrogen on the 
vessel wall. Hashimoto et al.8 used the same metlmd 
and demonstrated that endothelium-dependent 
vasodilatation i  the brachial artery varies during the 
menstrual cycle. It is greater during the follicular 
and luteal phases than during the menstrual phase, 
suggesting that endothelial vasodilatory function is 
positively modulated by endogenous ovarian hor- 
mones, especially estradiol. 
Short-term administration of estrogen has been 
shown to improve endothelium-dependent vasodi- 
latation of atherosclerotic coronary arteries of mon- 
keys after ovariectomy and of postmenopausal 
women.21, 22The effect of estrogen on endothelium- 
independent vasodilatation, however, is controver- 
sial. Reports in the literature both support and 
refute the aforementioned mechanism.2S, 4 In this 
study we found that estrogen enhanced endotheli- 
um-independent vasodilatation (direct smooth mus- 
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Fig. 1. Increase in blood flow (percentage of increase over baseline, mean and standard evia- 
tion bars) after iontophoresis of acetylcholine (black bars) and sodium nitroprusside (white bars) 
for premenopausal women (group 1), postmenopausal women not taking hormone replacement 
therapy (group 2), and postmenopausal women taldng hormone replacement therapy (group 
3). The response of group 2 during both measurements was significantly lower than that of 
groups 1 and 3 (p < 0.05), and no difference was observed between groups 1 and 3. 
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Fig. 2. Increase in blood flow (percentage of increase over baseline, mean and standard evi- 
ation bars) after iontophoresis of acetylcholine (black bars) and sodimn nitroprusside (white 
bars) among premenopausal women during menstruation (M phase) and during midcycle (P 
phase), The response during menstruation was significantly reduced compared with midcycle 
measurements of both acetylcholine and sodium nitroprusside (p < 0.05). 
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clc effect) significantly. The exact mechanism of  
action of  estrogen remains unclear. Estrogen may 
st imulate endothel ia l  nitr ic oxide synthesis, and 
because it has antioxidant propcrtics, estrogen may 
release or inhibit  degradat ion of nitric oxide.25, 26 
Other possiblc mcchanisms may be st imulation of  
release of  prostacyclin, inhibit ion of vasoconstrictor 
prostanoids, and alteration of calcium flux in vascu- 
lar smooth  musclc. The l ip id- lower ing cffcct of  
estrogen certainly plays a role in improving vascular 
funct ion  among persons with dyslipidemia.2-4, 27 
Estrogen also is lmown to inhibit  vasoconstriction in 
response to endothel in 1.28 Evaluation of the com- 
plete mechanisms of action of estrogen as a vasopro- 
tcctive and cardioprotective agent rcquires furthcr 
invest igat ion. Because endothe l ium-dependent  
vasodilatation is known to be impaired in the early 
stages of diabetes, hypertension, peripheral vascular 
disease, and athcrosclerosis, estrogen might have a 
role in prevention of  vascular complications and pro- 
gression of these diseases. 
This study demonstrated that endothe l ium-  
dependent  and endothe l ium- independent  vasodi- 
latation in the microcirculation is augmcntcd ur ing 
thc midcycle phasc of prcmenopausal women and in 
postmenopausal women using estrogen replacement 
therapy as compared with postmenopausal  women 
not  using replacement therapy. This may be consis- 
tent with an estrogenic effect on vascular dynamics. 
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DISCUSSION 
Dr. Magruder C. Donaldson (Boston, Mass.). I con- 
gratulate the authors on an excellent paper. Others have 
observed that people who have a relatively high estrogen 
level are protected from atherosclerosis. The question is 
whether we should consider the idea of a protocol that puts 
men on estrogen ata certain point in their lifespan. 
Dr. Subodh Arora. You make an interesting point. It 
would be interesting to study men with prostate cancer 
who are on estrogen and see how they compare with age- 
matched controls. The problem with studying men with 
prostate cancer on estrogen therapy is that most of them 
are started on fairly high doses. The complication rates 
with high doses can be high, but men on low-dose e tro- 
gen would certainly be a good group to compare with 
age-matched controls. 
Dr. Jeffrey L. Kaufman (Springfield, Mass.). I am 
impressed at the subtraction mage that you showed. I think 
there is a positive ffect, but I always have concern when I
see laser Doppler data as to the issue of electrical noise and 
the noise generated in the sampling technology in terms of 
finding a real difference. I hope that the manuscript cxplains 
this phenomenon and the absolute differences rather than 
percentage comparisons in evaluating the data. Some papers 
have not emphasized mat there can be much electrical noise 
with these instruments. Are these differences between the 
groups reflective of something beyond the noise factor? 
Dr. Arora. The answer to your question is yes. We 
actually have looked at the biological zero in every subject 
studied. This is done by first scanning the forearm skin 
with a blood pressure cuff on the arm and occluding the 
blood flow to the forearm completely to see how much 
background noise is picked up by the scanner. Then, the 
test is done with the cuff deflated. 
Dr. Jack L. Cronenwett (Lebanon, N.H.). Dr. Arora, 
I thought your study was an elegant study; it is great to see 
this ldnd of research being performed in the human situa- 
tion. I am having a little trouble understanding your con- 
clusion in terms of whether this is a problem at the 
endothelial cell level or the smooth muscle cell level. Your 
data showed the same effect with nitroprusside and with 
acetylcholine, and so it appears that this may be a primary 
defect in the smooth muscle cell response. I wonder if that 
is your conclusion. That is, have you been able to separate 
whether this is an endothelial cell difference or really just 
a primary smooth muscle cell issue? 
Dr. Arora. From our data, the response to acctyl- 
choline or the endothelial response was much greater than 
the smooth muscle response, but both elements seem to 
be definitely involved. As you know, there are estrogen 
receptors both in the endothelial cells and smooth muscle 
cells. In fact, some studies have shown that there might be 
more receptors in the smooth muscle cells than in the 
endothelial ceils, but that is still debatable. We think both 
the smooth muscle cells and the endothelial cells are actu- 
ally responsible for the vasodilatation. How much each 
contributes i  still unknown. 
Dr. Martha D. McDaniel (White River Junction, Vt.). 
In trying to put this in a clinical context, I wonder how 
you would explain the phenomenon you observed in as 
much as we believe that migraine headaches are vasodila- 
tory in nature and seem to be more prevalent during the 
menstrual period than during midcycle. 
Dr. Arora. We have thought about performing this 
study on women who have severe premenopausal and pre- 
menstrual symptoms, and I think that would be a very 
interesting study. It is hard to explain, with what we have 
found in normal healthy women, why some women get 
severe migraine during the menstrual period. You are right 
that it is vasodilatation that is thought o be the cause of 
these symptoms. This might be our next project. 
Dr. Anthony Whittemore (Boston, Mass.). In your 
reading, did you find any evidence that will allow you to 
correlate your findings with, perhaps, the incidence of 
coronary vasospasm? 
Dr. Arora. Data in the literature show a similar effect in 
the coronaries. Similar studies have been done, but these 
studies are all at the macrocirculation level where people 
have infused acetylcholine and estrogen into the coronary 
arteries and found profound vasodilatation. So, it certainly 
acts on the coronaries with profound vasodilatation. 
Dr. William W. Babson, Jr. (Plymouth, Mass.). I won- 
dered if you tried this on testosterone. Does testosterone 
have a similar effect toestrogen? 
Dr. Arora. We have not tried it with testosterone, but
testosterone apparently has the opposite ffect as estrogen. 
There are data to suggest that testosterone might actually 
cause vasoconstriction a d not vasodilatation, but these 
are anecdotal reports. There are no large studies in the lit- 
erature that look at the effect of testosterone on endothe- 
lial function. 
